Abstract
PARADIGM-HF showed a reduction in sudden cardiac death with Sacubitril-Valsartan (SV) use compared to enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However, it is not clear if there is significant reduction in ventricular arrhythmias due to SV.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
